2024-10-07T16:20:22-05:00 2023-12-31 410746749 CLIFTONLARSONALLEN LLP TWO INTERNATIONAL PLACE 22ND FLOOR BOSTON MA 02110 990 2023-01-01 263021330 EXCELLENCE THROUGH STEWARDSHIP EXCE 2029629200 1201 NEW YORK AVENUE NW 1300 WASHINGTON DC 20005 CHRISTOPHER HOLDGREVE EXECUTIVE DIRECTOR 2029629200 2024-10-04 1 0 LAURA J KENNEY P00202198 6177170831 2024-10-04 2023 2024-10-15 13:58:12Z GLOBAL STEWARDSHIP GROUP CHRISTOPHER HOLDGREVE 1201 NEW YORK AVENUE NW 1300 WASHINGTON DC 20005 557615 0 X WWW.EXCELLENCETHROUGHSTEWARDSHIP.ORG X 2008 DC TO PROMOTE THE RESPONSIBLE USE OF AGRICULTURAL BIOTECHNOLOGY. 12 12 4 28 0 0 70000 45000 474166 494288 0 0 0 18327 544166 557615 0 0 0 0 353940 456873 0 0 0 84578 60685 438518 517558 105648 40057 519931 477213 264209 181434 255722 295779 X TO PROMOTE THE RESPONSIBLE USE OF AGRICULTURAL BIOTECHNOLOGY, THE CONTINUED GLOBAL ADOPTION OF PLANT BIOTECHNOLOGY, AND THE ENHANCED VALUE OF BIOTECH-DERIVED PLANT PRODUCTS IN THE MARKETPLACE. 0 0 300891 494288 AUDIT PROGRAM:THE EXCELLENCE THROUGH STEWARDSHIP (ETS) AUDIT PROGRAM REQUIRES THIRD-PARTY AUDITS OF STEWARDSHIP AND QUALITY MANAGEMENT SYSTEMS FOR ALL PHASES OF THE PRODUCT LIFE CYCLE. QUALIFIED AUDITORS RECEIVE TRAINING BEFORE THEY CONDUCT AN AUDIT. INDEPENDENT THIRD-PARTY AUDITS WILL VERIFY IMPLEMENTATION OF EACH COMPANY'S STEWARDSHIP AND QUALITY MANAGEMENT SYSTEMS AND CONFIRM THAT THE SYSTEMS COMPLY WITH EXCELLENCE THROUGH STEWARDSHIP OBJECTIVES, PRINCIPLES, AND MANAGEMENT PRACTICES. AUDIT FOCUS AREAS INCLUDE MANAGEMENT SUPPORT AND COMMITMENT, MEASURABLE QUALITY OBJECTIVES AND STANDARDS, DOCUMENT CONTROL SYSTEMS, MATERIAL CONTROL AND IDENTIFICATION PRACTICES, COMPLIANCE AND VERIFICATION PRACTICES, MECHANISM FOR CONTINUOUS PROGRAM IMPROVEMENTS, AND CLEARLY DEFINED STEWARDSHIP PROGRAMS. IN 2023, 4 ADDITIONAL AUDITORS WERE TRAINED AND QUALIFIED TO CONDUCT AUDITS ACROSS ALL COMPONENTS OF THE "EXCELLENCE THROUGH STEWARDSHIP" PROCESS. 300891 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 2 0 1 4 1 0 0 0 0 1 1 0 0 0 0 0 X 12 12 0 0 0 0 1 1 1 1 1 0 0 1 1 1 1 0 1 1 0 0 X BIOTECHNOLOGY INNOVATION ORGANIZATI 2029629200 1201 NEW YORK AVENUE NW SUITE 1300 WASHINGTON DC 20005 SCOTT MUNDELL CHAIR 1.00 X X 0 0 0 ANNE PERONNET VICE CHAIR 1.00 X X 0 0 0 SCOTT HUBER TREASURER 1.00 X X 0 0 0 ANJA MATZK PHD BOARD MEMBER 1.00 X 0 0 0 SHIPING ZHANG PHD BOARD MEMBER 1.00 X 0 0 0 DAVID WHALEN BOARD MEMBER 1.00 X 0 0 0 HEATHER SPRAY BOARD MEMBER 1.00 X 0 0 0 RYAN JOHNSON BOARD MEMBER 1.00 X 0 0 0 PETER MCHUGH BOARD MEMBER 1.00 X 0 0 0 BETH ELLIKIDIS BOARD MEMBER 1.00 X 0 0 0 JENNIFER URNIKIS BOARD MEMBER 1.00 X 0 0 0 JOHN MCMURDY BOARD MEMBER 1.00 X 0 0 0 CHRISTOPHER HOLDGREVE EXECUTIVE DIRECTOR 40.00 X 201950 0 43347 201950 0 43347 1 0 1 0 0 45000 45000 MEMBERSHIP DUES 900099 494288 494288 494288 RECOVERY OF BAD DEBT 900099 18250 18250 MISCELLANEOUS 900099 77 77 18327 557615 494288 0 18327 245297 147178 98119 150820 90492 60328 7325 4395 2930 27171 16303 10868 26260 15756 10504 19559 19559 5163 5163 73 73 2175 1305 870 11803 7082 4721 1895 1137 758 ALL OTHER EXPENSES 17649 10559 7090 SUBSCRIPTIONS 1095 657 438 PRINTING AND GRAPHICS 900 540 360 EDUCATION AND TRAINING 250 250 123 74 49 517558 300891 216667 0 450724 418306 67750 57379 1457 1528 519931 477213 117734 35022 146475 146412 264209 181434 X 255722 295779 255722 295779 519931 477213 40057 0 X 0 1 X 1 0 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 615321 57706 57706 557615 0 557615 575264 57706 57706 517558 0 517558 X X 0 0 0 0 0 0 0 1 0 CHRISTOPHER HOLDGREVE EXECUTIVE DIRECTOR 196950 0 5000 0 0 0 6000 0 37347 0 245297 0 0 0 PART I, LINE 7 BOARD APPROVED PERFORMANCE BONUS OF $5,000 FOR EXECUTIVE DIRECTOR, CHRIS HOLDGREVE, WAS PAID IN JANUARY 2023 FOR 2022 PERFORMANCE. FORM 990, PART VI, SECTION A, LINE 1A THE BOARD DOES DELEGATE AUTHORITY TO AN EXECUTIVE COMMITTEE. THE COMMITTEE IS MADE UP OF THE BOARD OFFICERS AND THERE ARE NO MEMBERS WHO ARE NOT ON THE GOVERNING BODY. HOWEVER, NEITHER THE EXECUTIVE COMMITTEE NOR ANY OTHER COMMITTEE SHALL HAVE THE POWER TO AMEND THE ARTICLES OF INCORPORATION OR THE BYLAWS OF THE CORPORATION. THE CHAIR OF THE BOARD OF DIRECTORS SHALL SERVE AS THE CHAIR OF THE EXECUTIVE COMMITTEE. FORM 990, PART VI, SECTION A, LINE 6 THERE ARE TWO CLASSES OF MEMBERSHIP: 1) REGULAR VOTING MEMBERS: REGULAR VOTING MEMBERSHIP IS OPEN TO ANY CORPORATION, ACADEMIC, OR GOVERNMENTAL ORGANIZATION THAT UTILIZES PLANT BIOTECHNOLOGY IN RESEARCH, DEVELOPMENT, OR MANUFACTURE OF PLANT BIOTECHNOLOGY PRODUCTS OR OWNS, HANDLES, OR CONTROLS PLANT BIOTECHNOLOGY PRODUCTS; AND 2) ASSOCIATE MEMBERS: ASSOCIATE MEMBERSHIP IS FOR ANY NOT-FOR-PROFIT ORGANIZATION, ACADEMIC INSTITUTION, GOVERNMENT ENTITY OR INDIVIDUAL THAT SUPPORTS PLANT BIOTECHNOLOGY AND THE EXCELLENCE THROUGH STEWARDSHIP MISSION, BUT IS NOT DIRECTLY INVOLVED IN RESEARCH, DEVELOPMENT, OR MANUFACTURE OF PLANT BIOTECHNOLOGY PRODUCTS. ASSOCIATE MEMBERS ARE NOT ENTITLED TO VOTE UNLESS THE BOARD DETERMINES THAT AN ASSOCIATE MEMBER HAS DEMONSTRATED SUFFICIENT INTEREST AND INVESTMENT IN THE CORPORATION TO WARRANT BOARD MEMBERSHIP WITH FULL VOTING RIGHTS. FORM 990, PART VI, SECTION A, LINE 7A EACH REGULAR VOTING MEMBER THAT IS IN GOOD STANDING SHALL BE ENTITLED TO ONE (1) VOTE FOR THE ELECTION OF DIRECTORS TO THE BOARD OF DIRECTORS. THE BIOTECHNOLOGY INDUSTRY ORGANIZATION (BIO) IS THE FOUNDING ASSOCIATION MEMBER. THE BOARD OF DIRECTORS SHALL INCLUDE NOT MORE THAN TWO (2) BIO REPRESENTATIVES. THE BIO REPRESENTATIVES SHALL BE APPOINTED BY THE BIO PRESIDENT AND CEO. FORM 990, PART VI, SECTION A, LINE 7B EACH REGULAR VOTING MEMBER THAT IS IN GOOD STANDING SHALL BE ENTITLED TO ONE (1) VOTE FOR THE ELECTION OF DIRECTORS TO THE BOARD OF DIRECTORS AND ON ANY OTHER MATTER BROUGHT BEFORE THE FULL MEMBERSHIP. CHANGES TO THE ARTICLES OF INCORPORATION OR THE BYLAWS REQUIRE A MAJORITY VOTE OF THE BIO REPRESENTATIVES. BIO, IN ITS SOLE DISCRETION HAS THE RIGHT TO CEASE ALL INVOLVEMENT WITH ETS, AT WHICH TIME THE ARTICLE AND BYLAWS WOULD BE AMENDED TO REMOVE ALL REFERENCES TO BIO AND BIO REPRESENTATIVES. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS PREPARED BY TAX ADVISORS OF A NATIONAL ACCOUNTING FIRM WITH INFORMATION PROVIDED BY MANAGEMENT. BEFORE THE FORM 990 IS FILED, IT IS FIRST REVIEWED BY MANAGEMENT. THE FORM 990 IS THEN SUBMITTED TO ALL BOARD MEMBERS VIA EMAIL PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C THE ETS COORDINATOR VERIFIES ANNUALLY THAT ALL BOARD MEMBERS HAVE A COMPLETED, SIGNED, AND DATED CONFLICT OF INTEREST FORM. THE EXECUTIVE DIRECTOR REVIEWS ALL FORMS SUBMITTED AND IDENTIFIES THOSE WHERE CONFLICTS ARE NOTED. ANY CONFLICTS ARE BROUGHT TO THE EXECUTIVE COMMITTEE FOR FURTHER REVIEW AND POLICY ENFORCEMENT AS NECESSARY. IF THE CONFLICT INVOLVES AN EXECUTIVE COMMITTEE MEMBER, HE OR SHE IS RECUSED FROM THE DISCUSSION. FORM 990, PART VI, SECTION B, LINE 15A REVIEWS ARE BASED ON PERFORMANCE MANAGEMENT PLAN DEVELOPED EACH YEAR AND REVIEWED MID-YEAR. A COMPENSATION COMMITTEE, CHAIRED BY THE PREVIOUS BOARD CHAIR AND INCLUDING ADDITIONAL BOARD MEMBERS, IS RESPONSIBLE FOR REVIEWING THE PERFORMANCE OF THE EXECUTIVE DIRECTOR AND DETERMINING APPROPRIATE COMPENSATION. THE COMMITTEE USES COMPENSATION DATA FOR OTHER DIRECTORS AND TOP OFFICIALS OF ORGANIZATIONS OF SIMILAR SIZE AND COMPLEXITY WHEN DETERMINING THE EXECUTIVE DIRECTOR'S COMPENSATION. THE PROCESS WAS LAST UNDERTAKEN IN 2022. FORM 990, PART VI, SECTION B, LINE 15B: ETS DOES NOT HAVE ANY OTHER COMPENSATED INDIVIDUALS WHO FIT THE DEFINITION OF OFFICER OR KEY EMPLOYEE AND THEREFORE DOES NOT HAVE A FORMAL INDEPENDENT COMPENSATION REVIEW PROCESS AT THIS TIME. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST.